Zacks Research Issues Negative Outlook for Bruker Earnings

Bruker Corporation (NASDAQ:BRKR) – Equities researchers at Zacks Research lowered their Q3 2025 EPS estimates for Bruker in a report issued on Tuesday, October 21st. Zacks Research analyst Team now expects that the medical research company will post earnings of $0.33 per share for the quarter, down from their prior estimate of $0.37. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker’s Q4 2025 earnings at $0.85 EPS, FY2025 earnings at $1.97 EPS, Q1 2026 earnings at $0.44 EPS, Q2 2026 earnings at $0.43 EPS, Q3 2026 earnings at $0.53 EPS, Q4 2026 earnings at $0.69 EPS, FY2026 earnings at $2.09 EPS, Q1 2027 earnings at $0.53 EPS, Q2 2027 earnings at $0.59 EPS and FY2027 earnings at $2.46 EPS.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The firm had revenue of $797.40 million during the quarter, compared to analysts’ expectations of $811.17 million. During the same quarter in the previous year, the firm posted $0.52 EPS. Bruker’s revenue was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS.

Several other equities analysts have also recently issued reports on BRKR. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research report on Wednesday, October 8th. Bank of America reduced their price target on shares of Bruker from $61.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, June 26th. Citigroup reduced their price target on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a research report on Monday, August 4th. Barclays reduced their price target on shares of Bruker from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Thursday, October 2nd. Finally, Wells Fargo & Company reduced their price target on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 5th. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $51.00.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $38.78 on Wednesday. Bruker has a 1 year low of $28.53 and a 1 year high of $64.64. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. The company’s 50-day moving average is $33.76 and its 200 day moving average is $37.00. The stock has a market capitalization of $5.88 billion, a P/E ratio of 74.58, a P/E/G ratio of 5.33 and a beta of 1.20.

Institutional Investors Weigh In On Bruker

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Altfest L J & Co. Inc. purchased a new stake in Bruker in the third quarter worth about $439,000. SteelPeak Wealth LLC lifted its stake in shares of Bruker by 24.1% in the third quarter. SteelPeak Wealth LLC now owns 24,735 shares of the medical research company’s stock worth $805,000 after buying an additional 4,803 shares in the last quarter. Pacer Advisors Inc. bought a new position in shares of Bruker in the third quarter worth approximately $474,000. Thrivent Financial for Lutherans lifted its stake in shares of Bruker by 11.9% in the second quarter. Thrivent Financial for Lutherans now owns 29,032 shares of the medical research company’s stock worth $1,196,000 after buying an additional 3,085 shares in the last quarter. Finally, Advisory Services Network LLC lifted its stake in shares of Bruker by 35.9% in the second quarter. Advisory Services Network LLC now owns 9,535 shares of the medical research company’s stock worth $366,000 after buying an additional 2,520 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Insiders Place Their Bets

In other Bruker news, Director Cynthia M. Friend sold 3,535 shares of the company’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the sale, the director owned 18,016 shares in the company, valued at approximately $581,016. This represents a 16.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 27.30% of the company’s stock.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date was Tuesday, September 23rd. Bruker’s dividend payout ratio is 38.46%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.